You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly shares ... billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but short of analysts’ projections of $4.4 billion for Mounjaro and $2.1 ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Drugmakers will ask the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...